About UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 (B3GNT7) is a protein
from Homo sapiens identified by UniProt accession
Q8NFL0, 401 residues long.
MolForge cross-references it against 0 known binders and
123 disease associations.
Target properties
| Protein name | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 |
| UniProt accession | Q8NFL0 |
| Gene | B3GNT7 |
| Organism | Homo sapiens |
| Length | 401 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (123)
Diseases linked to this target (Open Targets).
- monocyte count · score 0.40
- blood protein measurement · score 0.33
- heart rate · score 0.33
- monocyte percentage of leukocytes · score 0.33
- body height · score 0.31
- neutrophil percentage of leukocytes · score 0.29
- resting heart rate · score 0.29
- vital capacity · score 0.28
- appendicular lean mass · score 0.28
- diet measurement · score 0.28
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8NFL0-F1 | alphafold | PREDICTED | 86.29 | — |
Amino-acid sequence (401 residues)
MSLWKKTVYR SLCLALALLV AVTVFQRSLT PGQFLQEPPP PTLEPQKAQK PNGQLVNPNN FWKNPKDVAA PTPMASQGPQ AWDVTTTNCS ANINLTHQPW FQVLEPQFRQ FLFYRHCRYF PMLLNHPEKC RGDVYLLVVV KSVITQHDRR EAIRQTWGRE RQSAGGGRGA VRTLFLLGTA SKQEERTHYQ QLLAYEDRLY GDILQWGFLD TFFNLTLKEI HFLKWLDIYC PHVPFIFKGD DDVFVNPTNL LEFLADRQPQ ENLFVGDVLQ HARPIRRKDN KYYIPGALYG KASYPPYAGG GGFLMAGSLA RRLHHACDTL ELYPIDDVFL GMCLEVLGVQ PTAHEGFKTF GISRNRNSRM NKEPCFFRAM LVVHKLLPPE LLAMWGLVHS NLTCSRKLQV L
Explore UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets